|Bid||323.50 x 6000|
|Ask||327.00 x 5000|
|Day's range||309.00 - 326.50|
|52-week range||273.00 - 839.00|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||51.45|
|Earnings date||29 Jan 2018 - 02 Feb 2018|
|Forward dividend & yield||1.25 (0.41%)|
|Ex-dividend date||28 Mar 2022|
|1y target est||109.00|
At today's virtual Annual General Shareholders' Meeting, the shareholders of Sartorius AG granted discharge to the Executive Board and the Supervisory Board and approved the boards' proposals by a large majority. They passed the resolution to pay dividends of 1,26 euros per preference share and 1.25 euros per ordinary share. The total amount disbursed will be 85.9 million euros. In the previous year, dividends were 0.71 euros per preference share and 0.70 euros per ordinary share.
On the occasion of its virtual Annual General Shareholders' Meeting today, life science company Sartorius takes a positive look back at the past year and provides shareholders with details on further growth prospects. "Life sciences and the biopharmaceutical industry are currently in a very dynamic and innovative phase. Significant progress is being made at an increasing pace in the development of advanced therapies, such as cell and gene therapy methods, and mRNA technology is showing great pot
The life science group Sartorius today has presented its 2021 Annual Report. Besides providing detailed information on its business performance, as well as on innovations, acquisitions and sustainability initiatives, the company also confirms its preliminary figures for fiscal 2021, which had already been published on January 27, 2022.